- Email: [email protected]
Malaria vaccine peptide Plasmodium falciparum circumsporozoite protein gene cloning in vaccinia virus
Patent Report
Heterologous virus peptide immunogen production: recombinant vaccine production in L-cell, Chinese hamster ovary, C127 cell culture Medico Labs World 8810 300; 29 December 1988 An immunogenic particle which comprises first and second peptide monomers is new. The particles are at least 10 nm in diameter. The two peptides are different and are from parasites or viruses, e.g. hepatitis B virus, hepatitis A virus, hepatitis non-A virus, hepatitis non-B virus, HIV virus, Plasmodium sp., foot-and-mouth disease virus, polio virus. Also new are: (1) recombinant DNA encoding the monomers; (2) host cells transfected with the recombinant DNA and recombinant DNA encoding the S peptide of hepatitis B virus; (3) recombinant proteins; (4) pharmaceutical compositions comprising the immunogenic peptides and optionally a carrier; (4) a method for transfecting host cells with the new DNA; (5) a method for producing recombinant proteins, which comprises culturing the transfected host cells and recovering the product; (6) a method for producing immunogenic particles; and (7) a method for preparing a pharmaceutical preparation. In an example, C127, L- or Chinese hamster ovary cells were transfected with plasmid pHBP252 and expressed immunogenic hepatitis B virus particles. 065-89
New human recombinant cytomegalo virus containing foreign gene: DNA sequence encoding HIV virus antisense mRNA or malarial surface antigen Syntro World 8810 311; 29 December 1988 A new virus comprises a DNA sequence essential for replication of a human cytomegalo virus and at least one foreign DNA sequence adapted for expression in a host. More specifically, the new virus is derived from a naturally occurring human cytomegalo virus and is attenuated. The foreign DNA sequence encodes a HIV virus anti-sense mRNA sequence, an antigenic polypeptide (e.g. a malarial surface protein), or fl-galactosidase (EC 3.2.1.23). The foreign DNA sequence is inserted into human cytomegalo virus at the EeoRI site of the 5.4 kb BamHI fragment, or as a replacement for the 5.5 kb Xho deletion fragment. The foreign DNA sequence is adapted for expression by an endogenous upstream human cytomegalo virus promoter (e.g. the immediate early promoter) or by a heterologous upstream promoter (e.g. the pseudorabies virus gpX promoter). Also new are plasmid pSY 1157 and plasmid pSY 1159. The new virus can be used in AIDS therapy or in vaccines, especially against malaria. Human cytomegalo virus is an ideal vector for the foreign DNA sequence since it is widespread and not appreciably pathogenic. 066-89
Canine corona virus vaccine production by infected cell culture; effective against dog corona virus and dog parvo virus infection Norden Lab. Eur. 295 057; 14 December 1988 A new vaccine for protecting dogs against dog corona virus (CCV) infection comprises a CCV cell-associated prepolymer (E2) protein (CAPP). The vaccine is prepared from a cell culture infected with CCV and is free of extracellular virus externalized during growth. Also new is a method for producing the vaccine which comprises: (1) infecting a cell culture with a multiplicity of infection of CCV of at least 0.2; (2) culturing the infected cells for at least 6-18 h; (3) discarding the spent culture medium; (4) disrupting the cells; (5) collecting the CAPP from the disrupted cells; and (6) combining the CAPP with a carrier. The vaccine is used for prophylaxis of CCV virus. Corona viruses cause eucellialitis, hepatitis, pneumonitis, neasophanyrigitis, peritonitis and gastroenteritis. The CAPP, as it exists in the
infected cells prior to particle formation, induces an immune response on i.p. administration to dogs, which protects them against symptoms of CCV infections. In contrast the whole virus (attenuated or inactivated) is relatively poorly immunoprotective. 067~89
Malaria vaccine peptide Plasmo~umfaiciparumcircumsporozoite protein gene cloning in vaccinia virus US Dept. Health Human Serv. US 7216 088; 6 December 1988 A new purified synthetic or recombinant peptide induces proliferation or activation of cytotoxic T-lymphocytes with specific activity against Plasmodiumfalciparum circumsporozoite (CS) protein. The peptide comprises residues 368-90 of the CS protein including the immunodominant epitope of the CS protein. The peptide is useful in malaria vaccine production. The induced cytotoxic T-lymphocytes recognize native CS protein and kill the cells infected with malaria sporozoites. Also new are: (1) a recombinant or synthetic vaccine against malaria; and (2) a method for controlling malarial infection by vaccinating humans with the synthetic or recombinant vaccine. The CS gene of P. falciparum is cloned into the EcoRI site of expression vector plasmid pcEXV-3, which contains the SV40 enhancer, early promoter, splice signals and polyadenylation signals. Mouse L cells were transfected with the CS gene of clone 7G8 of P. falciparum using the calcium phosphate precipitation method and plasmids pcEXV-3 and pSV2neo. Spleen cells of B10BR mice injected i.v. with recombinant vaccinia virus encoding CS protein were killed by the L-cells. 068-89
Parasitic nematode vaccine for human and animal protection fusion protein expression Biotechnol. Aus.; CSIRO World 8900 163; 12 January 1989 A protein derived from a parasitic nematode, Trichinella spiralis, Aneylostoma caninum, Stronoylus vuloaris, Ostertagia ostertagi, Ascaris suum, Toxasearis leonina, Uncinaria stenocephala, Trichuris vulpis, Dirofilaria immitis, Toxocara colubriformis, N ecator americanus, Anc ylostoma duodenale, Ascaris lumbricoides, Trichuris trichiura, Enterobius vermicularis, Stronglyoides stercorals, Wuchereria bancrofti, or Haemonchus contortus is useful as a human or animal vaccine. Also new are: (1) a DNA sequence encoding the protein or its mutants and analogues; (2) a method for producing the recombinant protein which comprises transforming a host with a vector, screening the transformants for the protein gene, and culturing the host; (3) a method for isolating the DNA, which encodes at least a part of the protein; (4) a fusion protein where the protein gene is fused to the Escherichia coil fl-galactosidase (EC 3.2.1.23) gene and under the control of the phase 2 PL tac promoter or the long repeat of M oloney leukemia virus; (5) vector plasmids pUR290, pUC18, pBTA593, pBTA597, pBTA598, etc.; (6) a vaccine; and (7) a transformed eukaryote or prokaryote. 069-89
Peptide capable of binding rubella immunoglobulin useful for rubella diagnosis and vaccine production; expression in Escherichia coli London Biotechnol. UK 2206 587; 11 January 1989 070-89
Synthetic peptide antigen corresponding to the major sites of T-lymphocyte recognition within the HIV virus envelope protein: recombinant vaccine production US Dept. Human Health Serv. US 7222 684; 6 December 1988
071-89
Vaccine, Vol. 7, August 1989 371
Heterologous virus peptide immunogen production: recombinant vaccine production in L-cell, Chinese hamster ovary, C127 cell culture Medico Labs World 8810 300; 29 December 1988 An immunogenic particle which comprises first and second peptide monomers is new. The particles are at least 10 nm in diameter. The two peptides are different and are from parasites or viruses, e.g. hepatitis B virus, hepatitis A virus, hepatitis non-A virus, hepatitis non-B virus, HIV virus, Plasmodium sp., foot-and-mouth disease virus, polio virus. Also new are: (1) recombinant DNA encoding the monomers; (2) host cells transfected with the recombinant DNA and recombinant DNA encoding the S peptide of hepatitis B virus; (3) recombinant proteins; (4) pharmaceutical compositions comprising the immunogenic peptides and optionally a carrier; (4) a method for transfecting host cells with the new DNA; (5) a method for producing recombinant proteins, which comprises culturing the transfected host cells and recovering the product; (6) a method for producing immunogenic particles; and (7) a method for preparing a pharmaceutical preparation. In an example, C127, L- or Chinese hamster ovary cells were transfected with plasmid pHBP252 and expressed immunogenic hepatitis B virus particles. 065-89
New human recombinant cytomegalo virus containing foreign gene: DNA sequence encoding HIV virus antisense mRNA or malarial surface antigen Syntro World 8810 311; 29 December 1988 A new virus comprises a DNA sequence essential for replication of a human cytomegalo virus and at least one foreign DNA sequence adapted for expression in a host. More specifically, the new virus is derived from a naturally occurring human cytomegalo virus and is attenuated. The foreign DNA sequence encodes a HIV virus anti-sense mRNA sequence, an antigenic polypeptide (e.g. a malarial surface protein), or fl-galactosidase (EC 3.2.1.23). The foreign DNA sequence is inserted into human cytomegalo virus at the EeoRI site of the 5.4 kb BamHI fragment, or as a replacement for the 5.5 kb Xho deletion fragment. The foreign DNA sequence is adapted for expression by an endogenous upstream human cytomegalo virus promoter (e.g. the immediate early promoter) or by a heterologous upstream promoter (e.g. the pseudorabies virus gpX promoter). Also new are plasmid pSY 1157 and plasmid pSY 1159. The new virus can be used in AIDS therapy or in vaccines, especially against malaria. Human cytomegalo virus is an ideal vector for the foreign DNA sequence since it is widespread and not appreciably pathogenic. 066-89
Canine corona virus vaccine production by infected cell culture; effective against dog corona virus and dog parvo virus infection Norden Lab. Eur. 295 057; 14 December 1988 A new vaccine for protecting dogs against dog corona virus (CCV) infection comprises a CCV cell-associated prepolymer (E2) protein (CAPP). The vaccine is prepared from a cell culture infected with CCV and is free of extracellular virus externalized during growth. Also new is a method for producing the vaccine which comprises: (1) infecting a cell culture with a multiplicity of infection of CCV of at least 0.2; (2) culturing the infected cells for at least 6-18 h; (3) discarding the spent culture medium; (4) disrupting the cells; (5) collecting the CAPP from the disrupted cells; and (6) combining the CAPP with a carrier. The vaccine is used for prophylaxis of CCV virus. Corona viruses cause eucellialitis, hepatitis, pneumonitis, neasophanyrigitis, peritonitis and gastroenteritis. The CAPP, as it exists in the
infected cells prior to particle formation, induces an immune response on i.p. administration to dogs, which protects them against symptoms of CCV infections. In contrast the whole virus (attenuated or inactivated) is relatively poorly immunoprotective. 067~89
Malaria vaccine peptide Plasmo~umfaiciparumcircumsporozoite protein gene cloning in vaccinia virus US Dept. Health Human Serv. US 7216 088; 6 December 1988 A new purified synthetic or recombinant peptide induces proliferation or activation of cytotoxic T-lymphocytes with specific activity against Plasmodiumfalciparum circumsporozoite (CS) protein. The peptide comprises residues 368-90 of the CS protein including the immunodominant epitope of the CS protein. The peptide is useful in malaria vaccine production. The induced cytotoxic T-lymphocytes recognize native CS protein and kill the cells infected with malaria sporozoites. Also new are: (1) a recombinant or synthetic vaccine against malaria; and (2) a method for controlling malarial infection by vaccinating humans with the synthetic or recombinant vaccine. The CS gene of P. falciparum is cloned into the EcoRI site of expression vector plasmid pcEXV-3, which contains the SV40 enhancer, early promoter, splice signals and polyadenylation signals. Mouse L cells were transfected with the CS gene of clone 7G8 of P. falciparum using the calcium phosphate precipitation method and plasmids pcEXV-3 and pSV2neo. Spleen cells of B10BR mice injected i.v. with recombinant vaccinia virus encoding CS protein were killed by the L-cells. 068-89
Parasitic nematode vaccine for human and animal protection fusion protein expression Biotechnol. Aus.; CSIRO World 8900 163; 12 January 1989 A protein derived from a parasitic nematode, Trichinella spiralis, Aneylostoma caninum, Stronoylus vuloaris, Ostertagia ostertagi, Ascaris suum, Toxasearis leonina, Uncinaria stenocephala, Trichuris vulpis, Dirofilaria immitis, Toxocara colubriformis, N ecator americanus, Anc ylostoma duodenale, Ascaris lumbricoides, Trichuris trichiura, Enterobius vermicularis, Stronglyoides stercorals, Wuchereria bancrofti, or Haemonchus contortus is useful as a human or animal vaccine. Also new are: (1) a DNA sequence encoding the protein or its mutants and analogues; (2) a method for producing the recombinant protein which comprises transforming a host with a vector, screening the transformants for the protein gene, and culturing the host; (3) a method for isolating the DNA, which encodes at least a part of the protein; (4) a fusion protein where the protein gene is fused to the Escherichia coil fl-galactosidase (EC 3.2.1.23) gene and under the control of the phase 2 PL tac promoter or the long repeat of M oloney leukemia virus; (5) vector plasmids pUR290, pUC18, pBTA593, pBTA597, pBTA598, etc.; (6) a vaccine; and (7) a transformed eukaryote or prokaryote. 069-89
Peptide capable of binding rubella immunoglobulin useful for rubella diagnosis and vaccine production; expression in Escherichia coli London Biotechnol. UK 2206 587; 11 January 1989 070-89
Synthetic peptide antigen corresponding to the major sites of T-lymphocyte recognition within the HIV virus envelope protein: recombinant vaccine production US Dept. Human Health Serv. US 7222 684; 6 December 1988
071-89
Vaccine, Vol. 7, August 1989 371